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Aims Iron deficiency is common in patients with heart failure (HF). In AFFIRM-AHF, ferric carboxymaltose (FCM) reduced
the risk of hospitalisations for HF (HHF) and improved quality of life vs. placebo in iron-deficient patients with a
recent episode of acute HF. The objective of this study was to estimate the cost-effectiveness of FCM compared with
placebo in iron-deficient patients with left ventricular ejection fraction <50%, stabilised after an episode of acute HF,
using data from the AFFIRM-AHF trial from Italian, UK, US and Swiss payer perspectives.
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Methods
and results
A lifetime Markov model was built to characterise outcomes in patients according to the AFFIRM-AHF trial.
Health states were defined using the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Subsequent
HHF were incorporated using a negative binomial regression model with cardiovascular and all-cause mortality
incorporated via parametric survival analysis. Direct healthcare costs (2020 GBP/USD/EUR/CHF) and utility values
were sourced from published literature and AFFIRM-AHF. Modelled outcomes indicated that treatment with FCM
was dominant (cost saving with additional health gains) in the UK, USA and Switzerland, and highly cost-effective
in Italy [incremental cost-effectiveness ratio (ICER) EUR 1269 per quality-adjusted life-year (QALY)]. Results were
driven by reduced costs for HHF events combined with QALY gains of 0.43–0.44, attributable to increased time
in higher KCCQ states (representing better functional outcomes). Sensitivity and subgroup analyses demonstrated
data robustness, with the ICER remaining dominant or highly cost-effective under a wide range of scenarios, including
increasing treatment costs and various patient subgroups, despite a moderate increase in costs for de novo HF and
smaller QALY gains for ischaemic aetiology.
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Conclusion Ferric carboxymaltose is estimated to be a highly cost-effective treatment across countries (Italy, UK, USA and
Switzerland) representing different healthcare systems.
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Introduction
Heart failure (HF) is a major global public health burden, affect-
ing an estimated 64 million people worldwide.1 Patients with
HF experience significantly impaired health-related quality of life
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.. (HRQoL),2 which correlates with increased hospitalisation times
and mortality rates.3 Indeed, HF is one of the biggest causes of
hospitalisations in the USA and Europe,4 and hospitalisations for HF
(HHF) are associated with long lengths of stay, a high readmission
rate and a large economic burden.1,5,6 Despite recent advances in
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HF treatment, prognosis remains poor1 and the significant morbid-
ity associated with HF places considerable strain on the healthcare
system.
Iron deficiency (ID) is prevalent in up to 50% of patients with
chronic HF7,8 and has been suggested to be present in up to 80%
of patients hospitalised for an episode of acute HF (AHF).9,10 In
patients with HF, ID is associated with reduced exercise capacity,11
impaired HRQoL,5 increased risk of hospitalisation and mortality11
regardless of the presence or absence of anaemia. This high
prevalence and the association with adverse outcomes mean that
ID represents a substantial unmet medical need in patients with
HF and presents a novel therapeutic target. Several recent studies
have demonstrated the efficacy and safety of intravenous (IV) ferric
carboxymaltose (FCM) for the improvement of the symptomatic
and functional health status among adults with HF with reduced
ejection fraction and ID.12,13
The results of AFFIRM-AHF, a randomised, double-bind,
placebo-controlled trial, demonstrated that treatment with FCM
reduced the risk of HHF and improved HRQoL, with no apparent
effect on the risk of cardiovascular (CV) death in patients who
were iron-deficient and had a left ventricular ejection fraction
(LVEF) <50% and were stabilised after a recent episode of AHF.12
Given the potential benefits of IV iron in this patient population,
the objective of this study was to estimate the cost-effectiveness
of FCM compared with placebo for the treatment of ID in patients
with HF from the payer perspective in four archetypes of health
systems: UK, USA, Italy and Switzerland.
Methods
Trial design and patient population
The rationale and design of the AFFIRM-AHF trial have been previously
published.14
Briefly, the AFFIRM-AHF was a randomised, double-blind,
placebo-controlled trial. Eligible patients were aged ≥18 years,
were hospitalised for AHF, and had a LVEF <50% and concomitant
ID, defined as serum ferritin <100 ng/mL, or 100–299 ng/mL with
transferrin saturation <20%. During the index hospitalisation, patients
received at least 40 mg of IV furosemide (or equivalent). Prior to
discharge, patients were randomised to receive either IV FCM or
placebo. The total FCM dose required was calculated using baseline
haemoglobin and body weight, and the repletion dose was admin-
istered at discharge and at week 6 (administered doses were up
to 1000 mg FCM or placebo). At weeks 12 and 24, if ID persisted,
additional FCM doses of 500 mg (or placebo) were administered.
The protocol was approved by the institutional review board at each
participating centre. Written informed consent was obtained from all
participants before any study-related procedures were performed.
Trial data included HHF data reporting first and subsequent events.
Hospitalisation for any reason was also recorded, from which HHF
events were removed to determine hospitalisation for non-HF (HnHF)
events. Twelve-item Kansas City Cardiomyopathy Questionnaire
(KCCQ-12) was used to evaluate the HF-specific health status at
baseline and weeks 2, 4, 6, 12, 24, 36 and 52. The KCCQ-12 is a
self-administered, disease-specific instrument that quantifies physical
function, symptoms (frequency, severity and recent change), social




















































































Target population and subgroups
The base case population was aligned with the AFFIRM-AHF trial
population.12 The following pre-specified subgroups were also anal-
ysed: LVEF <25%; LVEF 25–40%; LVEF 40–50%; ischaemic HF aetiol-
ogy; de novo HF or previous HF at index hospitalisation; anaemia status
(yes/no); and patients who were on triple therapy for HF at baseline
(one of angiotensin-converting enzyme inhibitor, angiotensin receptor
blocker, or angiotensin receptor–neprilysin inhibitor plus beta-blocker
plus mineralocorticoid receptor antagonist).
Model framework
A cohort state-transition Markov model was developed to estimate
outcomes in patients hospitalised for AHF with concomitant ID and
treated with either FCM or placebo in the UK, USA, Italy and Switzer-
land, based on a previously published economic model for patients with
HF.16 In brief, a decision node assigned patients to receive either FCM
or placebo per trial specifications. Each treatment arm consisted of
a cohort state-transition Markov model, which reflects disease pro-
gression between health states defined by KCCQ clinical summary
score (KCCQ-CSS) quartiles. Consistent with previous approaches,16
KCCQ quartiles were used to ensure an appropriate balance between
granularity and sufficient patient numbers within each subgroup to
allow for statistically robust analysis.
Events included HHF, HnHF, and select adverse events (AEs) mod-
elled as transient events captured as event-specific costs and util-
ity decrements applied to the utility in each health state. Mortality
(all-cause mortality and CV-specific) represented an absorbing state
that could be reached from any of the other health states. Figure 1
shows the model structure.
The model base case considers results on a per-patient basis; events
were scaled for presentation as rates per 1000 patients. The model
used a lifetime horizon with a cycle length of 4 weeks, reflecting
the chronic, progressive course of the disease. Model outcomes
were costs, life-years, quality-adjusted life-years (QALYs) and the
incremental cost-effectiveness ratio (ICER; cost per QALY gained). The
analysis was performed from the payer perspective. Country-specific
annual discount rates were applied: 3.5% for the UK and 3.0% for the
USA, Italy and Switzerland.
Disease progression
The clinical inputs used were derived from the AFFIRM-AHF trial,
using the intention-to-treat population dataset.12 Disease status
was captured using transitions between health states represented
by KCCQ-CSS quartiles of baseline scores. Transition probabilities
between KCCQ-CSS health states were derived using multinomial
model fits to individual patient-level data from the AFFIRM-AHF trial.
See online supplementary materials for additional details regarding
calculations.
The model captures mortality (CV and all-cause), hospitalisation
(HHF and HnHF) and AEs as events. Probabilities of CV mortality
and all-cause mortality over time were incorporated via parametric
multivariable survival analysis, adjusted for time-updated KCCQ-CSS
(to capture increased risk of mortality with worsening KCCQ-defined
state). Likewise, additional covariates were determined according
to clinically pre-specified subgroup definitions, comprising age, sex,
anaemia status, de novo and chronic HF diagnosis, estimated glomeru-
lar filtration rate, LVEF, and ischaemic origin of HF. Mortality in the
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Figure 1 Model structure. After the index hospitalisation for acute heart failure (AHF) event, disease progression was modelled through tran-
sitions between discrete health states characterised by the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS)
quartiles (Q1 through Q4). Events such as hospitalisation for heart failure (HHF), hospitalisation for non-heart failure reasons (HnHF), and
adverse events were modelled as transient events that occurred during a KCCQ-CSS-defined state, incurring the associated event-specific
costs and utility decrements. All-cause mortality (ACM) and cardiovascular (CV) mortality represent an absorbing state that could be reached
from any of the KCCQ-CSS health states. FCM, ferric carboxymaltose.
base case analysis was modelled using a Weibull distribution, which
was selected following assessment of model fits in accordance with
the recommendations for clinical trials published by the National Insti-
tute of Health and Care Excellence Decision Support Unit.17 General
mortality life tables (according to age and sex) were obtained from
the national statistics offices of the respective countries analysed (UK,
USA, Italy, Switzerland) with 2017 data as the most recent year consis-
tently available for all nations. The baseline mortality was adjusted using
country-specific World Health Organization estimates of CV mortal-
ity by age bracket to generate non-CV mortality life tables for use in
modelling.
Repeat events (HHF, HnHF) were modelled using generalised esti-
mating equations with a negative binomial distribution. AEs (classified
as serious) were selected on the basis of occurrence in at least 1%
of the trial population, independently of treatment arm. These were
atrial fibrillation, acute kidney injury, pneumonia, and sepsis; AEs of
cardiac origin were expected to be captured elsewhere (HHF events
and mortality). See online supplementary materials for further details.
Health-related quality of life
Quality-of-life analysis was performed using AFFIRM-AHF EuroQoL
5 Dimension 5 Level (EQ-5D-5L) data to which UK utility values
had been applied.12 Utility estimates for each health state were cal-
culated as the average utility index score across all patients in the
corresponding KCCQ-CSS quartile at baseline. Event-associated util-
ity decrements (HHF, HnHF, AEs) were estimated using a mixed effects
linear regression model to account for repeat measures. The equation







































.. influence EQ-5D-5L index score: age, sex, geographical region (West-
ern Europe, Eastern Europe, Latin America, and rest of world) and
KCCQ-CSS health state. Only events occurring in the 4 weeks prior to
an EQ-5D-5L assessment (constituting one model cycle) were included
for consideration. Utility decrements were calculated from trial data or
from literature in which too few events were recorded in the target
window (online supplementary materials).
Resource use and cost
A health state cost was assigned to each health state, including transient
event-specific costs. All patients were assigned a background resource
use associated with HF. Specific costs for events (HHF and AEs) were
applied as one-off costs at the time of the event. Treatment costs
associated with FCM were informed by mean reported dose per
patient. Most patients received the total dose within two infusions
(index hospital admission and week 6 study visit) with an average
total dose of 1354 mg. Because doses were typically administered in
1000 mg infusions (adjusted by patient characteristics according to the
study protocol),12 the cost for this infusion was applied in the first
cycle. The second cycle comprised the cost for the remaining mean
dose (354 mg) with no additional administration or monitoring costs
applied. Event costs were derived from published literature. All costs
were adjusted to 2020 currency units of the respective countries (UK,
USA, Switzerland, Italy; see online supplementary materials for details).
The willingness-to-pay (WTP) thresholds used for each country were
GBP20 000 for the UK, USD100 000 for the USA, CHF50 000 for
Switzerland and EUR30 000 for Italy.
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Table 1 Baseline patient characteristics
Ferric carboxymaltose (n = 558) Placebo (n = 550)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 71.20 (10.80) 70.89 (11.14)
Sex
Female 244 (43.7) 250 (45.5)
Male 314 (56.3) 300 (54.5)
Race
American Indian or Alaska Native 1 (0.2) 0
Asian 26 (4.7) 22 (4.0)
Black or African American 3 (0.5) 4 (0.7)
Other 0 1 (0.2)
White 528 (94.6) 523 (95.1)
Hypertension 468 (83.9) 471 (85.6)
Dyslipidaemia 300 (53.8) 292 (53.1)
Atrial fibrillation 314 (56.3) 305 (55.5)
Smoking 217 (38.9) 202 (36.7)
Myocardial infarction 229 (41.0) 213 (38.7)
Diabetes mellitus 227 (40.7) 243 (44.2)
Coronary revascularization 195 (34.9) 206 (37.5)
Angina pectoris 91 (16.3) 78 (14.2)
Stroke 53 (9.5) 66 (12.0)
Baseline diastolic blood pressure, mmHg 72.59 (10.31) 71.87 (9.91)
Baseline systolic blood pressure, mmHg 119.76 (15.24) 119.69 (15.64)
Baseline heart rate, bpm 74.49 (13.18) 74.23 (12.76)
Baseline BMI, kg/m2 28.13 (5.64) 28.03 (5.71)
Baseline eGFR (CKD-EPI), mL/min/1.73 m2 55.38 (21.36) 55.75 (23.07)
Baseline NYHA class 1 (0.2) 3 (0.5)
I 14 (2.5) 8 (1.5)
II 255 (45.7) 240 (43.6)
III 272 (48.7) 277 (50.4)
IV 16 (2.9) 22 (4.0)
Baseline LVEF, % 32.64 (9.59) 32.74 (9.94)
<25% 104 (18.6) 122 (22.2)
≥25% and <40% 288 (51.6) 243 (44.2)
≥40% and <50% 166 (29.7) 184 (33.5)
Heart failure aetiology
Ischaemic 265 (47.5) 257 (46.7)
Non-ischaemic 282 (50.5) 275 (50.0)
Unknown 11 (2.0) 18 (3.3)
Baseline haemoglobin category
Anaemica 292 (52.3) 312 (56.7)
Non-anaemic 265 (47.5) 238 (43.3)
Newly diagnosed heart failure 153 (27.4) 165 (30.0)
Patients with ARNI, yes/no 35 (6.3) 36 (6.5)
Patients with ACEi or ARB or ARNI, yes/no 420 (75.3) 414 (75.3)
Patients with beta-blockers 453 (81.2) 461 (83.8)
Patients with aldosterone antagonists 376 (67.4) 352 (64.0)
Patients with triple therapy 247 (44.3) 238 (43.3)
Baseline haemoglobin, g/dL 12.26 (1.62) 12.14 (1.60)
Baseline serum phosphorus, mg/dL 4.28 (12.58) 3.83 (0.98)
Baseline serum ferritin, ng/mL 83.85 (62.15) 88.47 (68.64)
Baseline TSAT, % 15.15 (8.31) 14.23 (7.47)
NT-proBNP pg/mL 4743 (2781–8128) 4684 (2785–8695)
For continuous variables, numbers represent mean (standard deviation); for categorical variables, numbers represent n (%).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CKD-EPI, Chronic
Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic
peptide; NYHA, New York Heart Association; TSAT, transferrin saturation.
aDefined as <12 g/dL in non-pregnant females and <13 g/dL in males.
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Sensitivity analyses
The robustness of the model to assumptions made about survival dis-
tributions, model parameters, utility values and costs was assessed
using deterministic sensitivity analysis (DSA), while probabilistic sen-
sitivity analysis (PSA) was used to assess overall uncertainty in the
modelled outcomes.
Results
Baseline characteristics of the modelled patient cohort are pre-
sented in Table 1, the utility values and country-specific costs
applied in the model are shown in Table 2 and online supplementary
materials, respectively.18
The modelled outcomes indicated that treatment with FCM was
associated with discounted QALY gains of 0.43, 0.43, 0.44 and
0.44, in the UK, Italy, Switzerland and USA, respectively (Table 3).
FCM was dominant (cost saving with additional health gain) in
the UK, USA, and Switzerland, and highly cost-effective in Italy
with an ICER of EUR1269/QALY gained. In the Italian setting,
the small incremental cost is attributable to the relatively higher
background HF maintenance cost in comparison to that in the
other countries. In any case, the ICER estimated in Italy is far
below the accepted threshold of EUR30 000/QALY. The QALY
gains (improved life expectancy) were attributable to a combination
of increased time spent in better KCCQ states (representing better
scores on symptom, physical and social functional scales) and a
reduction in HHF events, for patients who received FCM. Over
a lifetime horizon, treatment with FCM was associated with an
estimated 199 fewer HHF events per 1000 patients. The reduction
in HHF events is associated with cost savings of USD5422, GBP561,
EUR1389 and CHF2709 per average patient in the USA, UK, Italy
and Switzerland, respectively. The cost-effectiveness results were
largely driven by cost offsets associated with reduced HHF events
and QALY improvements.
Subgroup analysis
Ferric carboxymaltose remained either dominant or cost-effective
vs. current WTP thresholds in all subgroups analysed (Figure 2). In
all four countries, use of FCM vs. placebo in patients with de novo
HF was associated with the greatest cost increase per QALY vs. the
overall trial population (range: CHF-1, 205 in Switzerland to EUR1,
361 in Italy); nevertheless, FCM remained dominant vs. placebo in
the USA and Switzerland and cost-effective in the UK and Italy,
with ICERs remaining below the WTP threshold in each country. In
patients with a history of HF, the cost of FCM vs. placebo decreased
compared with the overall trial population, with FCM resulting in
greater cost savings in the UK, USA and Switzerland and improved
cost-effectiveness in Italy. The greatest cost savings vs. the overall
population were consistently seen in the LVEF <25% subgroup,
where cost differences ranged from USD –5117 in the USA to
EUR –108 in Italy. Patients in the de novo HF group had modestly
greater life expectancy (0.54–0.57 in this group vs. approximately
0.43 overall); the increase in costs for these patients was therefore
attributable to this modest survival benefit as they accrued greater




















































































Table 2 Utility inputs
Health state Mean SE Reference
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
KCCQ-CSS Q1: 0–<25 0.54 0.02 AFFIRM-AHF
KCCQ-CSS Q2: 25–<39 0.65 0.01 AFFIRM-AHF
KCCQ-CSS Q3: 39–<54 0.70 0.01 AFFIRM-AHF
KCCQ-CSS Q4: 54–<100 0.83 0.01 AFFIRM-AHF
Hospitalisation
Hospitalisation for HF −0.07 0.02 AFFIRM-AHF
Hospitalisation for non-HF −0.02 0.02 AFFIRM-AHF
Adverse events
Atrial fibrillation −0.02 0.11 AFFIRM-AHF
Pneumonia −0.10 0.08 AFFIRM-AHF
Acute kidney injury −0.04 0.09 AFFIRM-AHF
Sepsis −0.30 0.10a Galante et al.18
HF, heart failure; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire
clinical summary score; SE, standard error.
aAssumed to be 10% of the mean value.
the cost savings were driven by fewer HHF events, while the
mortality difference was minor. Given that patients who receive
triple therapy for HF are receiving a very high standard of care at
baseline, it is of particular relevance that, for these patients, FCM
is a dominant option in the USA, UK and Switzerland, and also
exhibits a very low ICER in Italy.
In terms of utility, the subgroup with HF of non-ischaemic
origin was associated with the greatest increase in QALYs gained
(0.50–0.52 QALYs) and the group of ischaemic origin the lowest
(0.35–0.36 QALYs). As in the overall analysis, this result was driven
by time spent in the KCCQ-defined health states, with more time
in the topmost quartiles for non-ischaemic patients.
In all subgroups, although the magnitude of change in QALYs
differed, there was a consistent net increase. The other compo-
nent of the ICER, change in costs, demonstrated either increased
cost-savings (LVEF <25%) or in the most extreme case, a moder-
ate increase in costs (de novo HF), but the result remained highly
cost-effective.
Sensitivity analysis
The robustness of model results was assessed through determin-
istic and probabilistic sensitivity analyses. Results of the PSA are
presented in Figure 3. For each country, the bulk of the simulations
falls to the right of the WTP threshold (Figure 3A), indicating these
results would be considered cost-effective at the indicated thresh-
old. To assess the cost-effectiveness across different WTP thresh-
olds, cost-effectiveness acceptability curves were also generated
(Figure 3B). A high proportion of simulations would be considered
cost-effective across a range of thresholds in the different coun-
tries for the parameters sampled. In the base case threshold WTP
definitions, 86.9%, 82.9%, 90.1% and 89.4% of simulations would
be considered cost-effective in the UK, USA, Switzerland and Italy,
respectively.
The DSA results are presented in the online supplementary
materials. Considering the time horizon, restricting the model
© 2021 Vifor Pharma. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Base-case results
Country Ferric carboxymaltose Placebo Incremental
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United Kingdom
Total costs GBP10 700 GBP10 839 –GBP139
Treatment (intervention) GBP242 GBP0 GBP242
Background medical management GBP3694 GBP3268 GBP426
Hospitalisation for HF GBP3177 GBP3738 –GBP561
Hospitalisation for non-HF GBP787 GBP774 GBP13
CV mortality GBP1831 GBP2006 –GBP175
Adverse events GBP969 GBP1053 –GBP84
Total LYs 4.21 3.72 0.49
Total QALYs 2.98 2.55 0.43
ICER – – Dominant
United States of America
Total costs USD67 475 USD70 896 –USD3421
Treatment (intervention) USD2112 USD0 USD2112
Background medical management USD8507 USD7508 USD998
Hospitalisation for HF USD31 141 USD36 564 –USD5422
Hospitalisation for non-HF USD9996 USD9809 USD187
CV mortality USD15 007 USD16 401 –USD1394
Adverse events USD1036 USD900 USD136
Total LYs 4.27 3.77 0.50
Total QALYs 3.02 2.58 0.44
ICER – – Dominant
Italy
Total costs EUR26 489 EUR25 939 EUR550
Treatment (intervention) EUR270 EUR0 EUR270
Background medical management EUR14 226 EUR12 572 EUR1654
Hospitalisation for HF EUR7915 EUR9305 –EUR1389
Hospitalisation for non-HF EUR1775 EUR1744 EUR31
CV mortality EUR1522 EUR1666 –EUR144
Adverse events EUR781 EUR653 EUR128
Total LYs 4.25 3.76 0.49
Total QALYs 3.01 2.57 0.43
ICER – – EUR1269/QALY
Switzerland
Total costs CHF45 028 CHF47 733 –CHF2705
Treatment (intervention) CHF379 CHF0 CHF379
Background medical management CHF5687 CHF5020 CHF667
Hospitalisation for HF CHF15 563 CHF18 272 –CHF2709
Hospitalisation for non-HF CHF544 CHF5734 CHF110
CV mortality CHF15 226 CHF16 638 –CHF1412
Adverse events CHF2330 CHF2070 CHF260
Total LYs 4.28 3.78 0.50
Total QALYs 3.03 2.59 0.44
ICER – – Dominant
CV, cardiovascular; HF, heart failure; ICER, incremental cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.
to a within-trial (1 year) horizon resulted in FCM dominance
for all countries. Over this short interval, small QALY increases
were observed combined with cost savings due to reduced HHF
events that overcame smaller cost increases due to HnHF and
treatment costs. In the present analysis, no additional monitoring








. protocol, patients in both arms would have received the same
level of care, including study visits where infusions would occur.
Increasing treatment costs in the DSA by 150% to partially account
for a scenario where the treatment may incur additional costs,
the result remained dominant for the UK, USA and Switzerland,
with an ICER of EUR1499 for Italy, well below the considered
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Figure 2 Subgroup analysis. Points are shown on the
cost-effectiveness plane for the mean value analysis of indi-
cated patient subgroups. Dashed lines correspond to the
willingness-to-pay threshold for each country. Points to the right
of the dashed line would be considered cost-effective at the
given willingness-to-pay threshold, while points to the right of
the y-axis [positive change in quality-adjusted life-year (QALY)]
and below the x-axis (decreased costs) are considered dominant.
CHF, Swiss Francs; EUR, Euros; GBP, Great Britain Pounds
Sterling; HF, heart failure; LVEF, left ventricular ejection fraction;
USD, United States Dollars.
WTP threshold. Similar patterns of dominance and ICERs were
observed for variations in utilities and distributions for mortality
modelling.
Discussion
In this base case analysis, management of ID with IV FCM vs.
placebo (in addition to standard HF therapy) in patients sta-



















































































.. cost-saving from a UK, US and Swiss health system perspective,
and cost-effective from an Italian health system perspective based
on the current WTP thresholds. The difference in a small incremen-
tal cost for gain in QALYs, as for Italy, is in part due to the higher
estimated background HF maintenance cost for Italy. The cost was
derived from the work of Rognoni and Gerzeli19 who, in perform-
ing an economic analysis of FCM in the Italian setting, reported
costs for a model based on New York Heart Association (NYHA)
classes. If these costs were lower, then, like the other countries, the
intervention tends towards dominance. We accept that there may
be alternative estimates for this maintenance cost, but we note that
changing this cost (per the deterministic sensitivity analysis) does
not change the conclusion and that the ICER in the Italian setting
only changes from dominance after year 1 (within trial analysis with
a time horizon of 1 year yields a result dominant for FCM).
In general, cost-effectiveness was mainly driven by cost offsets
associated with reductions in HHF, in addition to QALY gains
derived from greater time spent with a better HF-specific
health status with FCM vs. placebo. In previous published
cost-effectiveness analyses in HF, results were principally driven by
reductions in CV and all-cause mortality.16,20
In our analyses from the UK, Italy, Switzerland and US health
service perspectives, patients treated with FCM gained 0.43–0.44
QALYs compared with placebo. This gain in QALYs should be
viewed in the context of the AFFIRM-AHF population, who were
elderly with an impaired LVEF, a high prevalence of comorbidities,
and recent admission to hospital for a potentially life-threatening
event.12 Indeed, the average lifespan of patients discharged follow-
ing HHF has been previously estimated at approximately 5.5 years,
with an impaired LVEF associated with an even shorter life span.21
Thus, a gain of 0.43–0.44 QALYs represents a clinically meaning-
ful improvement in our patients. Similar QALY gains in patients
with HF and a reduced LVEF were observed with dapagliflozin
vs. placebo in the DAPA-HF trial (UK: 0.48)16 and with sacubi-
tril/valsartan vs. enalapril in the PARADIGM-HF trial (UK: 0.52;
Italy: ∼0.28; Switzerland: 0.42; and USA: 0.78).20,22,23 This was
despite the DAPA-HF and PARADIGM-HF trial populations being
younger (mean age∼66 and 64 vs. 71 years, respectively) and hav-
ing less severely elevated N-terminal pro B-type natriuretic peptide
(NT-proBNP, median across treatment groups: 1428–1446 and
1594–1631 vs. 4684–4743 pg/mL, respectively) compared with
AFFIRM-AHF.12,16,24 Additionally, CV mortality rates were gener-
ally lower in DAPA-HF compared with AFFIRM-AHF (11.5% over
a median of 18 months vs. 14.2% over 12 months in the placebo
group),12,16 indicating a baseline population with lower CV risk. It
is worth noting that reductions in CV and all-cause mortality were
major contributors to the QALY gains observed in DAPA-HF and
PARADIGM-HF,16,24 whereas in AFFIRM-AHF, the major contribu-
tor was a reduction in HHF. Thus, the QALY gains in AFFIRM-AHF
largely reflect clinically relevant improvements in a patient’s life
while they are alive.
An increase in time spent with a higher KCCQ-CSS (indicat-
ing better HF-specific health status) with FCM vs. placebo also
contributed to the QALY gains observed. Use of KCCQ-CSS
vs. NYHA class is a relatively novel approach to economic
evaluation in HF. While NYHA class is a physician-reported
© 2021 Vifor Pharma. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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outcome with four discrete categories, the KCCQ-CSS is
patient-reported and quantitatively measures symptom frequency,
symptom burden and physical limitation, providing a more pre-
cise reflection of clinical severity and limitations in patients
with HF.25 The estimated health utilities associated with the
different KCCQ-CSS quartiles in AFFIRM-AHF were similar to
those derived from DAPA-HF data, offering additional, external
validity.16
The reduction in HHF events with FCM vs. placebo in
AFFIRM-AHF translated into lower hospitalisation costs in all
four countries, offsetting FCM treatment costs and providing addi-
tional cost savings in the UK, USA and Switzerland. Importantly,
cost savings came not from reducing CV mortality, the effect on
which was minimal with FCM vs. placebo in AFFIRM-AHF, but
from preventing HHF. Given the high prevalence of ID in HF,7,8
the impact of FCM on HHF and related cost-savings could be

























. and treated for ID. Reducing hospitalisation rates is also an
important health-economic and resourcing advantage in the
COVID-19 era.26
Subgroup analyses revealed that treatment with FCM was highly
cost-effective vs. placebo in all four countries, irrespective of
characteristics such as anaemia status, LVEF, HF aetiology and HF
history, and in the context of a high baseline standard of care, such
as for patients receiving triple therapy.
Nevertheless, characteristics reflective of a more severe disease
state, such as a LVEF <25%, anaemia, and a history of HF, were
associated with greater cost savings. Similar results were demon-
strated in DAPA-HF, where better cost-effectiveness results were
observed in patients with longer HF duration, lower LVEF and
higher NT-proBNP.16 This is likely due to the higher frequency of
events expected in patients with a higher baseline CV risk and thus
a greater opportunity to prevent events from occurring through
treatment.
Figure 3 Probabilistic sensitivity results. Probabilistic sensitivity results are shown for incremental costs and benefits on the cost-effectiveness
plane (A). Individual points represent separate simulations based on random sampling of model parameters and the dashed line indicates the
willingness-to-pay threshold for each country. Points to the right of the line are considered cost-effective. In the cost-effectiveness acceptability
curves (B), the percentage of simulations is shown as a function of varying the willingness-to-pay threshold. CHF, Swiss Francs; EUR, Euros;
GBP, Great Britain Pounds Sterling; QALY, quality-adjusted life-year; USD, United States Dollars.
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Figure 3 Continued
This economic analysis was based on data for patients with
a recent AHF episode, representing a very high-risk subgroup
of patients with HF; however, the findings are applicable to all
patients with HF and align with those from prior economic
analyses in patients with chronic HF and ID: in the FAIR-HF
trial, FCM was cost-effective vs. placebo from UK,27 Spanish5 and
Swedish28 health service perspectives. Similarly, a pooled analysis
of patient-level data from FAIR-HF, FER-CARS-01, CONFIRM-HF
and EFFICACY-HF trials found that FCM was dominant vs. placebo
in an Italian healthcare setting19 and cost-saving over 5 years in a
French healthcare setting.29 These data support our findings and
suggest that FCM is cost-effective in a broad spectrum of patients
with HF and ID.
Limitations
The cost-effectiveness framework employed herein was designed
to predict whether the acquisition cost of FCM would be jus-
tified given its expected health gains and cost offsets. The data
suggest that, from the payers’ perspective, this is likely to be
the case; however, our analysis quantifies value from one stake-
holder’s view (the payer). For example, it considers the impact of
HHF reductions on costs, but does not evaluate whether there
is sufficient capacity within the system to cope with demand. Fur-
thermore, our analysis does not consider disease incidence and
prevalence over time which, for a chronic, progressive condition
such as HF that is associated with a high rate of hospitalisations
and readmissions,1,4,5 is an important limitation, particularly given
the continually expanding and increasingly ageing nature of the
HF population.1,6 Consequently, our analysis likely underestimates
the holistic value of FCM in terms of planning service delivery,
staffing, resource requirements and policy decisions; further stud-
ies investigating FCM from these perspectives would be beneficial.


















































. utility was converted into a single summary index using the UK
tariff. Ideally, we would have utilised country-specific utility values
to address regional variability; however, our objective was to pro-
vide an estimate of the cost-effectiveness of FCM from an interna-
tional perspective acknowledging that the cost profile across coun-
tries is considerable. The recent cost-effectiveness evaluation of
dapagliflozin in HF that used country-specific tariffs reported incre-
mental utility (QALY) gains that differed by 0.02 across countries,16
suggesting regional variation in utility is modest. Nevertheless, the
results of our analysis should be interpreted with this limitation in
mind.
A further limitation is the need to extrapolate 1 year of
follow-up data to a lifetime horizon, limiting the certainty of future
predictions. This includes the extrapolation of numerical differ-
ences in survival observed across trial arms. However, it is note-
worthy that the results remain robust even when restricting the
time horizon to 1 year.
In addition, although AFFIRM-AHF was a multinational trial with
sites across Europe, South America and Singapore, variations in
race were limited (95% of patients were white) and the represen-
tation from each country was modest.12 Thus, the trial population
does not necessarily represent the typical HF populations of the
four countries.
Conclusion
In conclusion, our results indicate the health-economic value of
IV FCM for the treatment of ID in patients stabilised after an
AHF episode, with cost-saving observed in the UK, USA and
Switzerland, and cost-effectiveness and QALY gains in all four
countries, including Italy. Therefore, FCM improves the lives of
patients with ID and HF while allowing health services to reclaim
treatment costs or, in certain cases, gain financially. Given the
© 2021 Vifor Pharma. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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prevalence of ID in HF, the potential for global cost savings from
reductions in HHF with FCM is substantial.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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